Drug intelligence / Profile preview

ASKG315 + pembrolizumab

Development stage: Unknown
Lead developer: AskGene Pharma
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

ASKG315 + pembrolizumab is a combination regimen under clinical investigation for the treatment of advanced solid tumors. ASKG315 is a novel engineered cytokine prodrug, specifically an interleukin-15 (IL-15) prodrug designed for proteolytic activation and targeted immune stimulation, developed using AskGene Pharma’s SmartKine® cytokine prodrug technology. Its mechanism extends the half-life of IL-15 and improves safety by restricting activation to the tumor microenvironment, stimulating natural killer (NK) cells and CD8+ T cells for anti-tumor activity. Pembrolizumab is a monoclonal antibody that blocks programmed cell death protein 1 (PD-1), thereby enhancing T-cell–mediated immune response against tumors. The combination aims to synergistically augment antitumor immunity through checkpoint inhibition and cytokine-mediated immune cell activation.

Other names: ASKG-315ASKG315ASKG 315ASKG215βIL-15 Fc fusion prodrugIL15 Fc fusion prodrugIL 15 Fc fusion prodrugprogrammed cell death protein 1 antibody

Targets

PDCD1 (Programmed cell death protein 1 receptor)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)

Beyond the preview

Go deeper on ASKG315 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASKG315 + pembrolizumab.

Explore the full profile